Nursing Elites

1. Which lab result should be abnormal in a child with hemophilia?

• A. Prothrombin time
• B. Bleeding time
• C. Platelet count
• D. Partial thromboplastin time

Correct answer: D

Rationale: In a child with hemophilia, the lab result that should be abnormal is the partial thromboplastin time (PTT). Hemophilia is a disorder that affects the clotting factors in the intrinsic pathway of coagulation, leading to a prolonged PTT. Prothrombin time (Choice A) assesses the extrinsic pathway and should be normal in hemophilia. Bleeding time (Choice B) evaluates platelet function, which is typically normal in hemophilia. Platelet count (Choice C) measures the number of platelets and is not directly affected by hemophilia.

2. What is a common complication of untreated type 1 diabetes in children?

• A. Diabetic ketoacidosis
• B. High blood pressure
• C. Asthma
• D. Frequent infections

Correct answer: A

Rationale: Diabetic ketoacidosis is a serious complication of untreated type 1 diabetes in children. It is characterized by high blood sugar levels, ketones in the urine, and acidosis. Prompt medical attention is required to manage this condition. High blood pressure (Choice B) can be a complication of diabetes but is not as directly linked to untreated type 1 diabetes as diabetic ketoacidosis. Asthma (Choice C) and frequent infections (Choice D) are not typically associated with untreated type 1 diabetes in children.

3. Before publication in a reputable journal, the findings of a research study must undergo scrutiny by experts in the field in a process known as what?

• A. peer review
• B. cohort review
• C. research intervention
• D. double-blind examination

Correct answer: A

Rationale: The correct answer is A: peer review. Before publication, research findings must undergo peer review, where experts in the field evaluate the validity and significance of the study. Choice B, cohort review, is incorrect as it does not involve the same level of evaluation by experts. Choice C, research intervention, is not a term used to describe the evaluation process before publication. Choice D, double-blind examination, refers to a study design where neither the participants nor the researchers know who is receiving a particular treatment, which is not the same as the peer review process.

4. How should the healthcare provider respond to a parent concerned about a child's short stature?

• A. Suggest the parent consult a nutritionist
• B. Recommend frequent growth hormone injections
• C. Advise monitoring for a few years before intervention
• D. Refer for a genetic evaluation

Correct answer: C

Rationale: When a parent expresses concern about a child's short stature, the initial approach should involve advising monitoring for a few years before considering any interventions. This allows for observation of the child's growth pattern and any potential underlying issues. Suggesting a nutritionist (Choice A) may not be necessary if there are no signs of nutritional deficiencies. Recommending growth hormone injections (Choice B) is premature without proper evaluation and diagnosis. Referring for a genetic evaluation (Choice D) can be considered later if monitoring shows atypical growth patterns or other concerning factors.

5. What should be monitored in a child receiving chemotherapy?

• A. Blood glucose levels
• B. Blood cell counts
• C. Weight gain
• D. Skin elasticity

Correct answer: B

Rationale: The correct answer is monitoring blood cell counts. During chemotherapy, it is crucial to monitor blood cell counts to detect potential side effects such as neutropenia (low white blood cell count) and anemia (low red blood cell count). These conditions can increase the risk of infections and fatigue. Monitoring blood glucose levels (Choice A) is not typically a primary concern in children receiving chemotherapy unless they have pre-existing conditions like diabetes. Weight gain (Choice C) and skin elasticity (Choice D) are not directly related to monitoring the effects of chemotherapy in children. Therefore, the most important parameter to monitor in a child receiving chemotherapy is blood cell counts.

Similar Questions